The entire world is experiencing an unprecedented increase in the number of aged individuals1. The number of people over the age of 65 is expected to reach 2 billion by the year 20502. Age is a significant risk factor for most major causes of mortality in the United States, including type 2 diabetes (T2D) and cardiovascular disease (CVD), and the financial impact of caring for the elderly is daunting. Medicare expenditures are expected to top $1 trillion just next year3. The high comorbidity of age-related diseases in the elderly limits the benefit that can be obtained by targeting any one chronic disease individually4. Therefore, there is a clear need to begin to test geroprotective interventions that have shown efficacy in preclinical models to determine if these agents simultaneously delay or even prevent multiple age-related conditions in humans. Each subject will undergo two MRI scans.
(EVERLAST) Clinical Evaluation of mTORC1 for Geroprotection Everolimus Aging Study
This project was funded by: NIH
The term of this project was: February 2023 to June 2023
The number of subjects scanned during this project was: 86